All Oncology News

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

A new method enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

Physical activity, from walking to strength training, helps boost recovery for patients after their stem cell transplants.

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Based on its previously demonstrated activity and tolerability in ES-SCLC, I-DXd will be examined in the phase 3 IDeate-Lung02 trial.

Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

Using AI to automate oncology insurance prior authorization submissions could help lighten the load for health care professionals and speed access to care.

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.